Q1 2020 Y-mAbs Therapeutics, Inc Earnings Call Transcript
Welcome to the Y-mAbs First Quarter 2020 Earnings Conference Call. The conference is being recorded.
(Operator Instructions) I would now like to turn the conference over to Thomas Gad, the Chairman and President.
Thank you, and thank you, everyone, for joining this call this morning. I assume most of us are still virtual, hopefully not for long. So despite of the extraordinary circumstances that we have been through in this first quarter, Y-mAbs actually had a great quarter of 2020. We believe we've made significant progress on executing our strategy and taking additional steps that will position us very well for our potential product launch of both naxitamab and omburtamab. We completed the submission of naxitamab BLA to the FDA in March as you know, and expect to complete the rolling BLA submission for omburtamab next month. We are also working very hard on our GD2-GD3 vaccine, which should also expand from a single-center trial into a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |